AstraZeneca’s Real-World Outcomes Deal With IMS Aims To Turn Treatment Data Into Business Decisions
This article was originally published in The Pink Sheet Daily
Executive Summary
Accessing IMS Health’s European electronic health records and jointly building a customized data analysis platform will inform AstraZeneca’s R&D priorities and support outcomes claims of newly-launched drugs.